A systematic review found that biological markers like brain activity patterns, inflammatory signals, and hormone changes may help predict who responds best to serotonergic psychedelic therapies such as psilocybin and ayahuasca. Consistent signals included changes in functional brain connectivity (especially in emotion-regulating regions) and modulation of cortisol levels. These markers could support more personalized psychedelic treatments for depression.